Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22063576 | 0.90 | PDE4D (0.48) | PDE4DPTAFRHIF1AEPAS1 | |
| SCHEMBL25860646 | 0.86 | ALDH1A1 (0.41) | PDE4DPTPN1PPARDGAA | |
| SCHEMBL22063759 | 0.84 | ACHE (0.48) | PTPN1PTAFR | |
| SCHEMBL25860652 | 0.82 | SLC6A3 (0.38) | — | |
| SCHEMBL22063573 | 0.81 | BACE1 (0.44) | — | |
| SCHEMBL22063647 | 0.68 | NFE2L2 (0.44) | — | |
| SCHEMBL18289658 | 0.67 | PDE4D (0.55) | PDE4D | |
| SCHEMBL22063652 | 0.67 | ALDH1A1 (0.37) | — | |
| SCHEMBL15394726 | 0.66 | PPARD (0.86) | ALOX5PTPN1PPARGPPARDGAA | |
| SCHEMBL16505784 | 0.66 | PDE4D (0.52) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | NORTHWESTERN UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | DUOX1, DUOX2, ALDH3A1 | PDE4D 4775/4885ALOX5 137/4885PTPN1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.